CFHR1

Across TCGA pan-cancer cohorts, CFHR1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CFHR1 data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CFHR1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CFHR1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, GBM, and LSCC are the cancer types where CFHR1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	II,III,IV	0.680	0.401	.016	7	view →
GBM	OS	Median	All	0.257	0.520	.001	5	view →
LSCC	DFS	Median	All	0.893	0.970	.012	5	view →
LUAD	OS	Quartile	II,III,IV	0.322	0.868	.017	2	view →
HNSC	OS	Tertile	All	0.796	0.581	.038	2	view →
CCRCC	OS	Median	II,III,IV	0.588	1.000	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CFHR1–PDAC (OS)

Open the PDAC breakdown →